• Explore /
  • Poster
  • / Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.

Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.

Abstract Poster

Authors

null

Giuseppe Saglio

University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy

Giuseppe Saglio , Timothy P. Hughes , Richard A. Larson , Surapol Issaragrilsil , Anna G. Turkina , Juan Luis Steegmann , Jose L. Lopez , Chiaki Nakaseko , Matt E. Kalaycio , Francoise Huguet , Charisse N. Kemp , Xiaolin Fan , Hans D. Menssen , Hagop M. Kantarjian , Andreas Hochhaus

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Leukemia, Myelodysplasia, and Transplantation

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Leukemia

Clinical Trial Registration Number

NCT00471497

Citation

J Clin Oncol 31, 2013 (suppl; abstr 7054^)

DOI

10.1200/jco.2013.31.15_suppl.7054

Abstract #

7054^

Poster Bd #

36F

Abstract Disclosures

Similar Posters

First Author: James E. Signorovitch

First Author: Richard A. Larson

First Author: Hagop Kantarjian

First Author: Benjamin J. Solomon